These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37874334)

  • 1. [Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review].
    Klemm J; von Deimling M; Fisch M; Kramer G; Tilki D; Steuber T; von Amsberg G; Hengstenberg C; Shariat SF
    Urologie; 2024 Mar; 63(3):262-268. PubMed ID: 37874334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
    Greiman AK; Keane TE
    Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.
    Dragomir A; Touma N; Hu J; Perreault S; Aprikian AG
    J Natl Compr Canc Netw; 2023 Feb; 21(2):163-171. PubMed ID: 36791755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
    Higano CS
    Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Toxicity of Androgen Deprivation Therapy.
    Boland J; Choi W; Lee M; Lin J
    Curr Cardiol Rep; 2021 Jul; 23(8):109. PubMed ID: 34216282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances with androgen deprivation therapy for prostate cancer.
    Yu EM; Aragon-Ching JB
    Expert Opin Pharmacother; 2022 Jun; 23(9):1015-1033. PubMed ID: 35108137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
    Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
    Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice.
    Kim J; Freeman K; Ayala A; Mullen M; Sun Z; Rhee JW
    Curr Oncol Rep; 2023 Sep; 25(9):965-977. PubMed ID: 37273124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiometabolic side effects of androgen deprivation therapy in prostate cancer.
    Lafontaine ML; Kokorovic A
    Curr Opin Support Palliat Care; 2022 Dec; 16(4):216-222. PubMed ID: 36349380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease.
    Margel D; Peer A; Ber Y; Shavit-Grievink L; Tabachnik T; Sela S; Witberg G; Baniel J; Kedar D; Duivenvoorden WCM; Rosenbaum E; Pinthus JH
    J Urol; 2019 Dec; 202(6):1199-1208. PubMed ID: 31188734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    Crawford ED; Hafron JM; Debruyne F; Wallis C; Chang S; Garnick MB
    J Urol; 2024 Jan; 211(1):63-70. PubMed ID: 37796473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic complications of androgen deprivation therapy for prostate cancer.
    Saylor PJ; Smith MR
    J Urol; 2009 May; 181(5):1998-2006; discussion 2007-8. PubMed ID: 19286225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
    Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
    Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
    Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
    Merseburger AS; Sedding D; Hüter K
    Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer.
    Cirne F; Aghel N; Petropoulos JA; Klotz L; Lenihan DJ; Saad F; Pinthus J; Leong DP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):253-262. PubMed ID: 33470403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer.
    Solanki AJ; Kamrava M; Posadas EM; Freedland SJ; Ballas L; Sandler HM; Bairey Merz CN; Atkins KM; Nikolova AP
    Cancer; 2024 Jun; 130(11):1916-1929. PubMed ID: 38529566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Therapy-Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy.
    Chen DY; Lee CH; Tsai ML; Hsieh MJ; Chuang CK; Pang ST; Chen SW; Tseng CN; Chang SH; Chu PH; Hsieh IC; Wu VC; Huang WK
    J Am Heart Assoc; 2023 Oct; 12(19):e030447. PubMed ID: 37750600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic effects of androgen deprivation therapy.
    Choi SM; Kam SC
    Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.